Выбор редакции

The Zacks Analyst Blog Highlights: Mondelez, Colgate-Palmolive, Stryker, Nike and Fifth Third Bancorp

For Immediate Release

Chicago, IL – September 26, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Mondelez (Nasdaq: MDLZ – Free Report), Colgate-Palmolive (NYSE: CL – Free Report), Stryker (NYSE: SYK – Free Report), Nike (NYSE: NKE – Free Report) and Fifth Third Bancorp (Nasdaq: FITB – Free Report).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Monday’s Analyst Blog:

Top Research Reports for Mondelez, Colgate-Palmolive & Stryker

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Mondelez (Nasdaq: MDLZFree Report), Colgate-Palmolive (NYSE: CLFree Report) and Stryker (NYSE: SYKFree Report). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Mondelez's shares have lost +10.8% in the last three months, compared with the -7.6% dip of the Zacks Food Preparation industry. However, the Zacks analyst likes Mondelez’s attractive portfolio of iconic brands, commanding presence in impulsive categories and fast-growing emerging markets. Mondelez’s margins have remained constantly strong backed by cost savings and productivity gains.

The company has a mostly positive record of earnings surprises in recent quarters. However, Mondelez’s volumes have been hurt since 2014 by the elasticity impact from higher pricing and category weakness because of soft consumer demand. Moreover, with a significant portion of its sales coming from international markets, currency is a significant top-line headwind.

(You can read the full research report on Mondelez here >>>).

Shares of Buy-rated Colgate-Palmolive are up +8.8% in the year-to-date period, outperforming the Zacks Consumer Staples sector, which has gained +8.6% over the same period. The Zacks analyst likes the progress made on its 2012 Restructuring Program and expects additional opportunities identified under the program to help reach the higher end of its previously stated cost and savings view.

Moreover, the company has been infamous among investors with its meet or beat earnings track record. However, the company’s sales missed expectations for the fifth straight quarter in second-quarter due to continued softness in North America and challenges in Asia-Pacific. Further, the company lagged sales estimates in 16 out of the trailing 17 quarters.

Nevertheless, the company remains focused on four fundamentals to boost profits including, increased spending on advertisements; innovation across portfolio; higher spends on e-commerce business and aggressively maximizing productivity. Also, its disciplined capital strategy bodes well. Estimates have been stable lately.

(You can read the full research report on Colgate-Palmolive here >>>).

Stryker’s shares have gained +21.2% over the last year, outperforming the Zacks Medical Products industry, which has increased +8.4% over the same period. Stryker announced the voluntary product recall of the Oral Care lineup recently. The recall is likely to adversely impact the company’s sales and operating income. Stryker exited the second quarter on a solid note, beating the Zacks Consensus Estimate on both counts. Solid performance in the MAKO platform drove revenues.

Upbeat guidance for the full year instills investor confidence on the stock. Stryker has a diversified product portfolio. Continued strong demand for hemorrhagic and ischemic stroke products and neuro-powered instruments boosted sales in the neurotechnology segment. However, volatility in foreign currency exchange is likely to impede revenue growth. Stryker also faces supply-side headwinds and has been grappling with issues in the spine business for long.

(You can read the full research report on Stryker here >>>).

Other noteworthy reports we are featuring today include Nike (NYSE: NKEFree Report) and Fifth Third Bancorp (Nasdaq: FITBFree Report).

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.

Get the full Report on MDLZ - FREE

Get the full Report on CL - FREE

Get the full Report on SYK - FREE

Get the full Report on NKE - FREE

Get the full Report on FITB - FREE

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

[email protected]


Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Fifth Third Bancorp (FITB): Free Stock Analysis Report
Mondelez International, Inc. (MDLZ): Free Stock Analysis Report
Stryker Corporation (SYK): Free Stock Analysis Report
Nike, Inc. (NKE): Free Stock Analysis Report
Colgate-Palmolive Company (CL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research